RESEARCH & DEVELOPMENT
HYBRID EXOSOMES: A Novel Platform for Cancer Therapy In the absence of an effective nanocarrier vehicle, traditional cancer treatment, tumor imaging, and immunotherapy remain ineffective. Artificial liposomes have been used to encapsulate bioactive compounds and release the payload continuously and stimuli-responsively, but they suffer from multiple drawbacks. Extracellular vesicles (EVs) are natural endogenous macromolecule transporters used for drug delivery, but adequate and repeatable loading of the EVs with therapeutic or imaging agents still limits their application as drug delivery systems. EV-liposome hybrids are a novel nanocarrier platform that can solve the challenges existing with individual nanocarrier systems and provide precise cancer detection and tailored treatment.
Manash K. Paul Scientist, Principal Investigator at UCLA
Introduction Effective cell-to-cell communication is essential for normal physiological homeostasis in multicellular organisms like humans. All bodily functions involve the coordinated interaction of cells. Extracellular vesicles (EVs) are one of the several processes through which cells interact with one another. EVs are extracellular, membrane-limited, mobile, cell-derived 14
P H AR M A F O C U S E U R O PE
ISSUE 01 - 2022
